Maverick Capital Ltd. Buys Shares of 698,740 Danaher Corporation $DHR

Key Points

• Maverick Capital Ltd. has purchased 698,740 shares of Danaher Corporation for approximately $143.2 million, making it 11th in its portfolio with 2.5% allocation.
• Danaher reported $1.80 EPS for its last quarter, surpassing analysts' expectations and indicating a revenue increase to $5.94 billion.
• The majority of Danaher's shares, at 79.05%, are owned by institutional investors, while the company has received a consensus rating of "Moderate Buy" from analysts.

Maverick Capital Ltd. acquired a new position in Danaher Corporation (NYSE:DHR - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 698,740 shares of the conglomerate's stock, valued at approximately $143,242,000. Danaher makes up about 2.5% of Maverick Capital Ltd.'s investment portfolio, making the stock its 11th biggest position. Maverick Capital Ltd. owned about 0.10% of Danaher as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Bank Pictet & Cie Europe AG increased its holdings in shares of Danaher by 22.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 192,731 shares of the conglomerate's stock worth $44,241,000 after acquiring an additional 35,730 shares in the last quarter. Gallagher Fiduciary Advisors LLC lifted its holdings in Danaher by 9.7% during the 4th quarter. Gallagher Fiduciary Advisors LLC now owns 1,065 shares of the conglomerate's stock worth $244,000 after purchasing an additional 94 shares during the last quarter. Accredited Wealth Management LLC bought a new position in shares of Danaher in the 4th quarter valued at $40,000. Aptus Capital Advisors LLC lifted its holdings in Danaher by 8.6% during the 4th quarter. Aptus Capital Advisors LLC now owns 7,078 shares of the conglomerate's stock worth $1,626,000 after buying an additional 562 shares during the period. Finally, Ancora Advisors LLC lifted its stake in shares of Danaher by 2.2% in the 4th quarter. Ancora Advisors LLC now owns 7,020 shares of the conglomerate's stock valued at $1,611,000 after purchasing an additional 149 shares during the period. Institutional investors and hedge funds own 79.05% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on DHR shares. Wells Fargo & Company reduced their target price on Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a report on Wednesday, July 23rd. Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective for the company in a report on Friday, July 11th. Barclays reiterated an "overweight" rating and set a $225.00 target price (up from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Finally, Robert W. Baird increased their price objective on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a report on Friday, July 18th. Seventeen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $246.35.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the business's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director owned 20,751 shares of the company's stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 11.20% of the stock is owned by corporate insiders.

Danaher Stock Performance

Shares of NYSE:DHR traded down $0.47 on Thursday, hitting $198.97. 3,627,515 shares of the company were exchanged, compared to its average volume of 4,153,999. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The stock's 50 day moving average price is $201.94 and its 200 day moving average price is $199.49. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $279.90. The firm has a market capitalization of $142.47 billion, a P/E ratio of 42.33, a price-to-earnings-growth ratio of 2.87 and a beta of 0.75.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. During the same quarter last year, the company posted $1.72 earnings per share. The firm's revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Sell-side analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.